



Citi Pharma Limited

February 29, 2024

The General Manager
Pakistan Stock Exchange Limited
Stock Exchange Building
Stock Exchange Road
Karachi.

Financial results for the 2nd quarter ended December 31, 2023

Dear Sir,

We have to inform you that the Board of Directors of the company in their meeting held on February 29, 2024 at Lahore have approved the financial statements for the 2nd Quarter ended on December 31, 2023 and recommended the following.

Cash Dividend	Nil
Bonus Shares	Nil
Right Shares	Nil
Any other entitlement/corporate action	Nil
Any other Price sensitive information	Nil

Financial Performance:

While reviewing the Company financial performance for the quarter ended, the Board appreciated the efforts of the management in the area of operation and posting the financial results.

Financial results of the company for the 2nd quarter ended December 31, 2023 are enclosed.

Quarterly report of the Company for the quarter ended December 31, 2023 will be transmitted through PUCARS separately, within the specified time.

Yours Sincerely,

Rizwan Ahmad
Chief Executive Officer



Cc:

Executive Director/HOD, Offsite-II, Department
Supervision Division, Securities & Exchange Commission of Pakistan



588 - Q, Johar Town, Lahore - Pakistan



3KM. Head Balloki Road, Phool Nagar, District Kasur - Pakistan



Head Office : +92. 42. 35316587 - 90 | Factory : +92. 49. 4510189, +92. 49. 4513392



www.citipharma.com.pk



Citi Pharma Limited

CITI PHARMA LIMITED
CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS (UN-AUDITED)
FOR THE HALF YEAR ENDED DECEMBER 31, 2023

Notes	Three month ended		Six Month Ended	
	December 31, 2023	December 31, 2022	December 31, 2023	December 31, 2022
	-----Rupees-----			
Sales- Net	3,275,164,830	3,052,797,729	5,976,393,097	6,170,872,085
Cost of Sales	(2,649,999,438)	(2,507,759,970)	(5,104,759,709)	(5,255,444,173)
Gross Profit	625,165,392	545,037,759	871,633,388	915,427,912
Administrative Expenses	51,252,284	51,873,819	99,514,835	101,588,824
Selling Expenses	31,504,344	32,818,897	70,138,398	70,482,274
	(82,756,628)	(84,692,716)	(169,653,233)	(172,071,098)
Operating Profit	542,408,764	460,345,042	701,980,155	743,356,814
Financial (Cost) /Income	(70,165,726)	35,451,281	(156,974,215)	(121,602,607)
	472,243,038	495,796,323	545,005,940	621,754,207
Other Income/(Loss)	157,403,690	4,935,455	263,611,872	52,533,589
	629,646,727	500,731,778	808,617,812	674,287,796
Other Expenses	(43,148,644)	(38,150,815)	(55,493,379)	(42,370,485)
Profit Before Taxation	586,498,083	462,580,963	753,124,433	631,917,310
Taxation	(210,897,441)	(167,852,676)	(283,072,250)	(191,280,386)
Profit for the Period	375,600,643	294,728,287	470,052,183	440,636,924
Earnings per share (EPS) - Basic and Diluted	1.64	1.29	2.06	1.93



588 - Q, Johar Town, Lahore - Pakistan



3KM. Head Balloki Road, Phool Nagar, District Kasur - Pakistan



Head Office : +92. 42. 35316587 - 90 | Factory : +92. 49. 4510189, +92. 49. 4513392



www.citipharma.com.pk